AbbVie Inc. (ABBV)
3 Cheap Stocks to Buy With Your Tax Refund Check
The average tax refund in 2024 was $3,138, which was similar to the $3,167 it averaged the previous year. While tax refunds will vary depending on a person's individual financial situation, if you receive one, it can provide you with some extra cash you can put toward paying down debt, adding to savings, or perhaps even investing in stocks.
2 Dividend Stocks to Buy for a Lifetime of Passive Income
Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation maintains its dividend program, the more attractive it is to income seekers, all else being equal.
AbbVie Inc. (ABBV) TD Cowen 45th Annual Health Care Conference (Transcript)
AbbVie Inc. (NYSE:ABBV ) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Company Participants Scott T. Reents - Executive Vice President and Chief Financial Officer Jeffrey R.
Here's How to Play AbbVie Stock as it Enters the Obesity Space
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
The Dividend Aristocrats Ranked By Quality Scores: March 2025
S&P Dow Jones Indices added three new members to the S&P 500 Dividend Aristocrats Index, expanding it to 69 companies. I rank Dividend Aristocrats by quality scores, presenting undervalued and overvalued stocks with detailed metrics and fair value estimates. My quality scoring system uses six indicators, each worth 5 points, for a maximum score of 30, categorizing stocks from Exceptional to Inferior.
Healthy Returns: AbbVie is the newest potential weight loss drug market player
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS conference gets underway in Vegas.
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
AbbVie (ABBV) closed the most recent trading day at $211.48, moving +1.17% from the previous trading session.
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
On Monday, AbbVie Inc ABBV and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a Phase 1 clinical trial.
AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal
AbbVie (ABBV) has agreed to license a weight-loss drug currently in development from Danish biotech firm Gubra for up to about $2.2 billion, signaling its entry in the obesity treatment market.
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.
4 Sectors That Thrive When Inflation Runs Hot
On February 28, investors will get the January reading of the Personal Consumption Expenditure (PCE) index. Spoiler alert: it's expected to show inflation continues to run hot.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Imagine being able to buy a machine that would work day after day and year after year to make you money. Now imagine being able to buy several such machines.
